Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.

Autor: Martin-Blondel, Guillaume, Ruiz, Stéphanie, Murris, Marlène, Faguer, Stanilas, Duhalde, Véronigue, Eyvrard, Frédéric, Izopet, Jacques, Mansuy, Jean-Michel, Rolland, Yves, Delavigne, Karen, Guimbaud, Rosine, Pugnet, Grégory, Conil, Jean-Marie, Georges, Bernard, Delobel, Pierre, Minville, Vincent, Sifontes, Stein Silva, Concordet, Didier, Gandia, Peggy
Zdroj: Clinical Infectious Diseases; Dec2020, Vol. 71 Issue 11, p2962-2964, 3p, 1 Chart, 1 Graph
Abstrakt: Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index